Daniel J George
Overview
Explore the profile of Daniel J George including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
291
Citations
8687
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shore N, George D, Spratt D, De La Cerda J
Future Oncol
. 2025 Mar;
:1-5.
PMID: 40051382
Relugolix is a once-daily oral gonadotropin-releasing hormone antagonist that was approved by the U.S. Food and Drug Administration in 2020 for the treatment of advanced prostate cancer. Relugolix is commonly...
2.
Raval A, Lunacsek O, Korn M, Littleton N, Constantinovici N, George D
JCO Oncol Pract
. 2025 Feb;
:OP2400690.
PMID: 39919261
Purpose: Treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has evolved with robust clinical trial evidence on the benefits of combining androgen-deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPIs; abiraterone,...
3.
Al Abo M, Foo W, Howard L, McGue S, Lacroix B, Kephart J, et al.
NPJ Precis Oncol
. 2025 Jan;
9(1):30.
PMID: 39880920
Black men suffer disproportionately from prostate cancer (PCa) compared to men of other races and ethnicities. Comparing the molecular landscape of PCa among Black and White patients has the potential...
4.
Hwang J, Hwang J, Holl E, Holl E, Wu Y, Agarwal A, et al.
JCI Insight
. 2025 Jan;
10(4).
PMID: 39773530
Since multiple front-line immune checkpoint inhibitor-based (ICI-based) combinations are approved for metastatic renal cell carcinoma, biomarkers predicting for ICI responses are needed past clinical prognostication scores and transcriptome gene expression...
5.
Shore N, Nielsen S, Esplin E, Antonarakis E, Barata P, Beer T, et al.
JCO Oncol Pract
. 2024 Dec;
OP2400626.
PMID: 39700441
Indications for and implications of germline genetic testing (GGT) in patients with prostate cancer have expanded over the past decade, particularly related to precision therapies and management. GGT has become...
6.
Agarwal N, George D, Klaassen Z, Sandin R, Butcher J, Ribbands A, et al.
JAMA Netw Open
. 2024 Dec;
7(12):e2448707.
PMID: 39652349
Importance: Clarifying the underutilization of treatment intensification (TI) for metastatic castration-sensitive prostate cancer (mCSPC) may improve implementation of evidence-based medicine and survival outcomes. Objective: To investigate physicians' beliefs about TI...
7.
Berg S, La Rosa S, Zhang T, Pierorazio P, Albiges L, Beckermann K, et al.
Urol Oncol
. 2024 Nov;
43(3):135-146.
PMID: 39500687
Modern advances in systemic and localized therapies for patients with renal cell carcinoma (RCC) have significantly improved patients' outcomes. If disease progression occurs after initial treatment, clinicians often have multiple...
8.
Beer T, George D, Shore N, Winters-Stone K, Wefel J, Verholen F, et al.
Oncologist
. 2024 Oct;
PMID: 39450762
Background: Androgen receptor inhibitors (ARIs) are approved for the treatment of advanced prostate cancer; however, some patients may experience symptoms and side effects that hinder their physical functioning. The Timed...
9.
Gillessen S, Turco F, Davis I, Efstathiou J, Fizazi K, James N, et al.
Eur Urol
. 2024 Oct;
87(2):157-216.
PMID: 39394013
Background And Objective: Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The...
10.
Kaye D, Lee H, Gordee A, George D, Scales Jr C, Ubel P, et al.
Am J Manag Care
. 2024 Sep;
30(9):e274-e281.
PMID: 39302261
Objectives: The high costs of cancer care can cause significant harm to patients and society. Prostate cancer, the leading nonskin malignancy in men, is responsible for the second-highest out-of-pocket (OOP)...